Moreover, tumor-derived EVs enriched in TGFβ have been shown to inhibit IL-2-induced T-cell proliferation and to induce regulatory T cell (Treg) phenotype in acute myeloid leukemia (AML) [144], mesothelioma [145], and colorectal cancer [146]. The gene discussed is IL2; the disease is acute myeloid leukemia.